Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
- Registration Number
- NCT00656539
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs and symptoms of blepharitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- diagnosis of moderate to severe chronic posterior blepharitis
- If female of childbearing potential, are non-pregnant and non-lactating
Read More
Exclusion Criteria
- had ocular surface surgery (LASIK, refractive, pterygium) within the past year
- unwilling to discontinue use of contact lenses during the study
- have glaucoma
- unable or unwilling to withhold the use of eyelid scrubs during the study
- have a serious systemic disease or uncontrolled medical condition that in the judgment of the investigator could confound study assessments or limit compliance
- currently using any preserved topical ocular medications (with the exception of unpreserved tear substitutes) at the time of entry into the study or during study participation
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 AzaSite® AzaSite®
- Primary Outcome Measures
Name Time Method Change in clinical signs and symptoms associated with blepharitis 4 weeks
- Secondary Outcome Measures
Name Time Method Standard ocular safety assessments 4 weeks
Trial Locations
- Locations (1)
Ophthalmic Consultants of Long Island
🇺🇸Lynbrook, New York, United States